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Pulmonary Epithelioid Hemangioendothelioma is a rare and low grade tumor of endothelial origin found
in the lungs. At onset patients are usually asymptomatic or present with non-speciﬁc symptoms. Chest
imaging shows the presence of multiple, bilateral small nodules and diagnosis usually requires a lung
biopsy. At this time there is no standardized treatment regimen and the prognosis is variable.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Our patient is a 65-year-old male that presented to the emer-
gency room with constant left sided anterior chest pain for the
previous ﬁve days. Prior to his presentation he was asymptomatic
and in the process of recovering from surgery on his trigger ﬁnger.
He has degenerative disk disease of the lumbar spine, well
controlled diabetes, hypercholesterolemia, and hypertension. The
patient has a 20-pack-year smoking history and quit 32 years ago.
On physical examination, therewas localized tenderness in the area
where the patient reported chest pain and the lung examination
was normal. A CT angiogram ruled out a pulmonary embolism but
did reveal multiple, well deﬁned, and irregularly shaped, bilateral
nodules. The largest of the nodules in the right lower lobe
measured 2 cm in size. The CT scan also revealed a possible lytic
lesion in the left second rib, and a sclerotic lesion located on the
posterior portion of the 10th rib. A ﬁne needle aspirate of the right
lower lobe lesion as well as that of the left second rib were non-
diagnostic, but did reveal atypical cells. A CT scan of the abdomen
and pelvis showed no abnormalities and a FDG-PET scan showed
faint tracer uptake in one of the right lower lobe nodules. Thissidharthrmehta@gmail.com
-NC-ND license.nodule had an SUV of 3.5 and the background demonstrated an SUV
of 2.7. The left second rib demonstrated an increased hyper meta-
bolic activity of SUV of 14. The patient underwent a VATS lung
biopsy with wedge resection of the nodule in the right lower lobe.
The wedge resection contained multiple ﬁrm white nodules. One
nodule measured 1  0.6  0.5 cm, a second nodule measured
0.6  0.3  0.2 cm and additional smaller nodules measured up to
0.2 cm in diameter. Microscopic examination revealed multiple
nodular areas of eosinophilic material containing cells with small
uniform nuclei. Some of these cells had prominent intra-
cytoplasmic vacuoles. These cells stained positive with immuno-
histochemical markers for endothelial cells, CD31 and CD34, sup-
porting the diagnosis of Epithelioid Hemangioendothelioma (EHE)
(Figs. 1e4).
EHE is a rare vascular tumor of intermediate behavior that was
ﬁrst described by Weiss in 1982 as an Intravascular Broncho-
Alveolar Tumor (IVBAT).17 Pulmonary Epithelioid Hemangioendo-
thelioma (PEH) is a rare, low grade tumor of endothelial origin17,6
and can be found in many organ systems including the lungs,
liver, bone, soft tissue and can be found sequentially, or simulta-
neously.5When this occurs it can be hard to determine of the tumor
is multicentric or a primary tumor with metastases to other
tissues.5 PEH is initially recognized on a chest radiograph or CT scan
with the presence of unilateral or bilateral nodules which range in
Fig. 1. CD-31 stain at 200 magniﬁcation. Fig. 3. Hematoxylin and eosin at 200 magniﬁcation.
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The problem with this radiological presentation is that it is non-
speciﬁc. Many physicians would consider a PET scan an important
tool used to rule out malignant lung diseases; However, in our
patient, only one nodule showed FDG uptake and a negative PET
scan in PEH patients is not unheard of.4 There are two possible
explanations that attempt to relate the malignancy of a nodule to
the FDG uptake. The ﬁrst is that a larger nodule may show a higher
FDG uptake, but the PET scan can fail to detect nodules smaller than
6 mm in diameter. Secondly, a greater FDG uptake can represent
a more clinically malignant potential and the lack of tracer uptake
can be evidence of a more benign character.
The diagnosis of PEH is made on the basis of histopathological
features which are conﬁrmed using immunohistochemical stain-
ing. CD34, CD31 and Factor VIII are the well-recognized endothelial
cell markers although a new marker, Nuclear Fli-1, a protein that is
expressed in endothelial cells as well as in T-cells and megakar-
yocytes, is being considered for use as a marker for PEH. Gill et al.
found that Nuclear Fli-1 was detected in 100 percent of their EHE
cases and found that FLI-1, CD34 and CD31 were the markers most
sensitive for EHE. It was also found that FLI-1 immuno-staining
demonstrated better sensitivity than CD34 and better speciﬁcity
than CD31.7 PEH is closely associated with arterioles, venules, andFig. 2. CD-34 stain at 200 magniﬁcation.lymphatic vessels and often display an intra-alveolar growth
pattern.17,18 EHE and subsequently PEH demonstrates reactivity for
factor VIII-related antigen (99%), CD31 (86%), and CD34 (94%).18
Calciﬁcation is commonly seen on the histology, but radiological
calciﬁcation is quite rare8 and PEH does not show necrosis, cyto-
logical atypia or a high mitotic index.13 Cellular pleomorphism,
mitotic activity, necrosis and extensive cellular spindling are cyto-
logic features that predict aggressive behavior. Unfortunately there
is no clear deﬁnition of malignant EHE or malignant PEH. PEH is
known to have biological behavior intermediate between
a hemangioma and a conventional angiosarcoma.
Pulmonary involvement is relatively rare with pulmonary EHE
being approximately 19% of all EHE cases.10 Other commonly
involved organ systems are the liver and bone with multi-organ
involvement quite common in EHE. Multi-organ involvement of
both the bone and lung is even rarer at 10% of all multi-organ
involvement with the most common being liver and bone
involvement.10 In a study of 93 patients distant metastasis was
conﬁrmed in 47 patients.2 The most common was hepatic metas-
tasis (22.6%) followed by pleural metastasis (20.4%) and lymph
node metastasis (10.8%).2
The diagnosis of EHE is often incidental (Table 1) as a majority of
patients are usually asymptomatic or have minor symptoms. OurFig. 4. Hematoxylin and eosin at 400 magniﬁcation.
Table 1
Review of the clinical, pathological and radiological features of published cases and reviews of PEH.
Name of study/
Authors
Female/Male Age Symptoms Radiography PET Metastasis Immuno features
Our case Male 66 Chest pain & left anterior
rib pain
Multiple bilateral Pos 1 nodule None CD31, CD34
Amin case report Female 70 Non-related Unilateral single
nodule
Not performed Lymph node and pleural VIII, CD34
Amin lit review
(n ¼ 93)
Female/Male
(73%/27%)
40.1 Symptomatic/Asymptomatic
(50.5%/49.5%)
Unilateral/Bilateral
(12.2%/78.9%)
Not measured Distant/Hepatic/Pleural/
Lymph (50.5%/22.6%/20.4%/
10.8%)
Factor VIII, CD31, CD34,
vimentin
Bagan (n ¼ 80) Female/Male
(63.8%/36.2%)
39.4 Symptomatic/Asymptomatic
(42.%/48.7)
Unilateral/Bilateral
(23.7%/76.2%)
No 38 70% VIII, CD 31, CD34
Cazzufﬁ case Male 67 Dyspnea and cough Multiple bilateral Negative Spleen and liver Factor VIII, CD31, Cd34
Cazzufﬁ data 3:1 Ratio 40.1 Weight loss, fatigue,
and respiratory symptom
Multiple bilateral Positive%?? Lymph, liver, bone Factor VIII, CD31, Cd34
Cronin Female 35 Multiple bilateral None No Factor VIII, CD31, CD34
Jinghong Female 20 No complaints Multiple Bilateral Not performed No FactornVIII, CD 31, CD34
Joo Lee Female 31 Upper back, and bilateral
shoulder pain
Unilateral and
vertebral bodies
Bone scan Multiple bone metastasis a-sma, Vimentin, weak
for CD34
Mhoyan Female 25 Chest pain, generalized
weakness
Multiple bilateral Not performed No Factor VIII, CD 31, CD34
Okamura Female 19 None Multiple bilateral Pos 1 nodule None Factor VIII, CD34
Shraim Male 51 Dry cough, SOBexertion, Multiple pleural Not performed Skin, anterior ab wall Factorn VIII, CD 31, CD34
Tochigi Woman 5th
Decade
None Unilateral multiple Not performed No Vimentin, CD31, FLI-1, CD34
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rior rib pain. Given the rarity of this tumor, the demographic
information is quite variable. Previous reports have suggested that
EHE is often found in women in ratio’s ranging from 3:1 female to
male ratio to a 2:1 female to male involvement. Patients age in
range from 19 to 70 years, with an average onset in the 4th decade.
Patients have been reported to live for up to 20 years5,8 with no
changes in tumor size or aggressiveness. There is even a report of
a patient surviving 10 years without any treatment.14
Pulmonary involvement of EHE can be quite variable in its
prognosis and the suggested risk factors have been quite variable.
When PEH was ﬁrst reported as IVBAT by Dial et al. in 1983, they
observed that the poor prognostic factors were the presence of
respiratory symptoms at presentation, lymphatic spread, pleural
invasion, extensive intravascular spread, and hepatic metastases.
Further research by Kitaichi et al., found that pleural effusion and
spindle tumor cells were unfavorable prognostic factors. A medline
literature review by Bagan et al. found that pleural effusion, signif-
icant loss of weight, and anemia were factors of a poor prognosis.
When analyzing the long term survival of PEH patients, Bagan et al.
discovered that patients could be placed into two categories:
asymptomatic patients with nodules (median survival of 15 years)
and patients with symptoms of vascular endothelial cell prolifera-
tion. The 5-year survival of patients with pleural effusion was 2%
whereas survival of the population without effusion was 73%.3 The
5-year survival ratewas at one point reported to be between 47 and
71%butanexaminationof an internetbasedEHEregistrybyLauet al.
found the 1 year survival rate to be 90% and 73% at 5 years. In Amin’s
review of 93 patients, they were able to reveal that male, symp-
tomatic patients, pleural effusion, metastases and lymph node
metastases were signiﬁcant risk factors. The study of the online
registry by Lau et al. found that the only signiﬁcant risk factors were
male sex, diagnosis in middle age, uncontained spread, and
involvementof threeofmorebones all correlatedwithpoor survival.
Various therapeutic modalities have been used in attempts to
either stopor slow the progression of PEH. Because of the rarity of this
condition there is no standard of agreed upon treatment. In patients
with a unilateral nodule a surgical resection is possible.9 In situations
of surgical resection as a form of treatment, use of a PET scan allows
one to resect aggressive PEH nodules.16 Patients with lymph node
metastases have undergone a surgical resection but due to the lownumberof patients, the prognostic value remainsunclear.15 Theuseof
various chemotherapies has been reported for metastatic or unre-
sectable PEH, but with variable effectiveness.12 The use of interferon-
2a found that pulmonary lesions regressed slightly and some bene-
ﬁcial results have been obtained with the use of bevacizumab. Other
proposed treatments include azathioprine,1,4,11 thalidomide and
multiplewedge resection. It is interesting to note that corticosteroids
have been suggested as a possible form of treatment3,4 because the
neoplastic cells express glucocorticoid receptors. For patients with
diffuse PEH it is has been suggested that hormonal therapy could be
used if the neoplastic cells express estrogen or progesterone recep-
tors. Although no cases have been reported to be positive for ER-a or
PR, there is a single report of a patient testing positive for ER-B.2 Lau
et al.’ study of the online registry found that 26% of patients chose
medical treatments and 22% chose to simply wait and observe the
disease. However, all of these treatment options represent single case
reports or an analysis of a cohort of single case reports and lack
convincing evidence of beneﬁt.Author contribution
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